HomeCompareGNFT vs EPRT

GNFT vs EPRT: Dividend Comparison 2026

GNFT yields 22.35% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNFT wins by $20.9K in total portfolio value
10 years
GNFT
GNFT
● Live price
22.35%
Share price
$8.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$84.2K
Annual income
$8,592.87
Full GNFT calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GNFT vs EPRT

📍 GNFT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNFTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNFT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNFT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNFT
Annual income on $10K today (after 15% tax)
$1,899.44/yr
After 10yr DRIP, annual income (after tax)
$7,303.94/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $3,610.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNFT + EPRT for your $10,000?

GNFT: 50%EPRT: 50%
100% EPRT50/50100% GNFT
Portfolio after 10yr
$73.8K
Annual income
$10,716.79/yr
Blended yield
14.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GNFT
Analyst Ratings
6
Buy
1
Sell
Consensus: Buy
Price Target
$13.00
+45.3% upside vs current
Range: $13.00 — $13.00
Altman Z
-0.1
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNFT buys
0
EPRT buys
0
No recent congressional trades found for GNFT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNFTEPRT
Forward yield22.35%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$84.2K$63.4K
Annual income after 10y$8,592.87$12,840.73
Total dividends collected$50.6K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$13.00$35.50

Year-by-year: GNFT vs EPRT ($10,000, DRIP)

YearGNFT PortfolioGNFT Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$12,935$2,234.64$11,205$505.18+$1.7KGNFT
2$16,541$2,701.33$12,672$682.46+$3.9KGNFT
3$20,928$3,228.58$14,490$930.48+$6.4KGNFT
4$26,210$3,817.51$16,786$1,282.69+$9.4KGNFT
5$32,513$4,468.32$19,753$1,791.56+$12.8KGNFT
6$39,970$5,180.24$23,677$2,541.64+$16.3KGNFT
7$48,719$5,951.60$29,008$3,672.99+$19.7KGNFT
8$58,909$6,779.83$36,463$5,425.08+$22.4KGNFT
9$70,694$7,661.60$47,238$8,221.57+$23.5KGNFT
10$84,236$8,592.87$63,385$12,840.73+$20.9KGNFT

GNFT vs EPRT: Complete Analysis 2026

GNFTStock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Full GNFT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GNFT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNFT vs SCHDGNFT vs JEPIGNFT vs OGNFT vs KOGNFT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.